Craig-Hallum Maintains Buy on MiMedx Group, Raises Price Target to $8
Craig-Hallum analyst Chase Knickerbocker maintains MiMedx Group (NASDAQ:MDXG) with a Buy and raises the price target from $6 to $8.
Read original at benzingaStocks · News reference
MIMEDX Acquires Sanara MedTech For ~$350M
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 29, 2026, 8:02 PM
- Checked
- Jul 29, 2026, 8:01 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Cantor Fitzgerald Reiterates Overweight on MiMedx Group, Maintains $8 Price Target
Cantor Fitzgerald analyst Sarah James reiterates MiMedx Group (NASDAQ:MDXG) with a Overweight and maintains $8 price target.
Read original at benzinga8-K/A filing — MIMEDX GROUP, INC. (MDXG)
Filed: 2026-08-11 AccNo: 0001376339-26-000082 Size: 208 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarMeta Posts Mixed Q2 Results, Joins Coursera, Qualcomm And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures rise, Meta shares drop 9.4%, Teladoc Health and Rentokil Initial fall after mixed financial results.
Read original at benzingaSanara MedTech Q2 EPS $(0.05) Misses $0.02 Estimate, Sales $28.137M Miss $28.950M Estimate
Sanara MedTech (NASDAQ:SMTI) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $0.02 by 350 percent. This is a 78.26 percent increase over losses of $(0.23) per share from the
Read original at benzingaHalper Sadeh LLC is Investigating Whether FBRX, LXFR, SMTI, MKTX are Obtaining Fair Deals for their Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether insiders are receiving substantial benefits unavailable to ordinary shareholders and whether transaction terms limit competing offers. The investigations cover Forte Biosciences' sale to argenx, Luxfer Holdings' sale to Wynnchurch Capital affiliates, Sanara MedTech's sale to MiMedx Group, and MarketAxess Holdings' sale to Intercontinental Exchange.
Read original at globenewswire-inc